Bio-Rad Laboratories’ Post

Our latest post spotlights a groundbreaking study recently published in the Journal of Hematology and Oncology. 🎉 Titled "Cholesterol-Conjugated siRNA Accumulates in Different Hematopoietic and Lymphoid Cells," this research dives into the potential of small interfering RNA (siRNA) in overcoming drug resistance in hematological malignancies. 🔍 The study delves into the challenges of delivering siRNA effectively to target cells and tissues, a key hurdle in biomedical applications. By attaching siRNA to cholesterol residues, researchers observed a significant increase in cellular uptake across various cell lines and primary cells. 🔬 Notably, the study found that the efficiency of siRNA accumulation depended on the length of the linker connecting cholesterol and siRNA. Moreover, Ch-siRNA showed promising results in various leukemia types and primary peripheral blood mononuclear cells, offering potential avenues for improved treatment strategies. 📖 Dive deeper into the research by accessing the full article here: https://lnkd.in/gSny2_bc Stay tuned for more updates on cutting-edge research in hematology and oncology! 💡 #ResearchHighlight #ScienceNews #Hematology #Oncology

📄 [Press release] – MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT 🩸 Key highlights: ✅ DSMB recommends proceeding as planned without modifications ✅ MaaT033 has shown to have an acceptable safety profile and was well tolerated in patients treated for blood cancers and receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). 🦠Phase 2b trial PHOEBUS, the largest one to date for a microbiome therapy in oncology, is an international, multi-center, randomized, double-blind, testing MaaT033, an oral freeze-dried formulation against placebo. https://lnkd.in/emffi3dR #Microbiome #BloodCancer #Cancer #DSMB #Safety

HISTORY OF ASPARAGINASE TO TREAT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA : The use of asparaginase to treat patients with ALL can be traced to the discovery by Kidd[5] in 1953 that guinea pig serum regressed Gardner 6C3HED lymphosarcoma xenografts implanted subcutaneously in mice. In a series of studies, Broome subsequently demonstrated that asparaginase is responsible for the anti-lymphoma effect of guinea pig serum. The anti-leukemic effect of asparaginase is due to the fact that lymphoblastic leukemia cells are unable to synthesize adequate amounts of L-asparagine (Asn) and, therefore, depend on extracellular sources. Asparaginase catalyzes the conversion of Asn to aspartic acid and ammonia, thereby depleting serum Asn and starving leukemic cells of the Asn necessary for DNA, RNA, and protein synthesis, leading ultimately to cell death. #Lasparaginase #VHB #AcuteLymphoblasticLeukemia #ALL #cancer #oncology #oncologycare #Leucoginase

Exciting new data from our research group! 🎉 Tyrosine kinase inhibitors (TKI) have revolutionized the treatment of patients with chronic myeloid leukemia (CML). Patients who achieve sustained deep molecular response are eligible for treatment discontinuation. DES-CML is an ongoing phase 2 multicentric discontinuation trial. This study aimed to assess the impact of BCR-ABL transcript kinetics during TKI de-escalation and discontinuation phases on treatment-free survival. https://lnkd.in/e584sUyj #chronicmyeloidleukemia #cml #leukemia #hematology #oncology #biomarkers

At the 2024 Great Debates & Updates in Hematologic Malignancies meeting in New York, Jia Ruan, MD, PhD, Weill Cornell Medicine, shares various active evaluations and topics of interest within the #MCL treatment landscape. Learn more: https://lnkd.in/eKH3jRC3 #GDUHem #GDU #GDUHem2024 #Oncology #Oncologist #OncologyNews #MantleCellLymphoma #Hematology

Here is the recent article published in Nature that demonstrates a transient perturbation of transcriptional silencing, mediated by Polycomb group proteins, is sufficient to induce cancer in Drosophila, highlighting the importance of epigenomic alterations in tumorigenesis. Nice piece of work. #oncology #cancer #epigenetics #drugdiscovery https://lnkd.in/ec9599nS

Ibrutinib sold under the brand name Imbruvica among others is a type of medication called a kinase inhibitor, which is used to treat various blood cancers and also a serious complication of allogeneic stem cell transplants called chronic graft versus host disease (cGVHD). Ibrutinib helps to slow down how quickly certain blood cancers progress by working against cancerous B cells, a type of white blood cell. It does this by blocking Bruton's tyrosine kinase (BTK) signaling. BTK is a protein found on B cells that instructs B cells to remain alive and multiply. Ibrutinib also blocks the activity of a similar protein called interleukin-2-inducible T-cell kinase (ITK). It's thought that this action and it's ability to block BTK helps in cGVHD. Contact us for more details: sales@royalpharma.in . . . #RoyalPharma #RoyalPharmaIndia #ibrutinib #Imbruvica #BloodCancerTreatment #CancerMedication #CancerTherapy #Oncology #Hematology

Our newest paper on 61 TP53-mutated AML - Amer Zeidan Yale School of Medicine #AcuteMyeloidLeukemia #Cancer #IntegratedAnalysis #OncoDaily #Oncology #YaleUniversity

#cancerresearch #oncology https://lnkd.in/dsJME9a8 Abstract #Copper, an essential trace element that exists in oxidized and reduced forms, has pivotal roles in a variety of biological processes, including redox chemistry, enzymatic reactions, mitochondrial respiration, #iron #metabolism, #autophagy and immune modulation; maintaining copper homeostasis is crucial as both its deficiency and its excess are deleterious. Dysregulated copper metabolism has a dual role in #tumorigenesis and cancer therapy. Specifically, #cuproplasia describes copper-dependent cell growth and proliferation, including hyperplasia, metaplasia and neoplasia, whereas #cuproptosis refers to a mitochondrial pathway of cell death triggered by excessive copper exposure and subsequent proteotoxic stress (although complex interactions between cuproptosis and other cell death mechanisms, such as ferroptosis, are likely and remain enigmatic). In this Review, we summarize advances in our understanding of copper metabolism, the molecular machineries underlying cuproplasia and cuproptosis, and their potential targeting for cancer therapy. These new findings advance the rapidly expanding field of translational cancer research focused on metal compounds.

Nature Medicine: Insights for precision oncology integrating genomic & clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme 1) In a study, published in Nature Medicine, more than nine out of every 10 brain tumours and most bowel and lung cancers exhibited genetic changes that could guide decisions about surgery or specific treatments. 2) In glioblastoma multiforme, small variants were present in 94% of cases and copy number aberrations in at least one gene in 58% of cases. 3) In more than 10% of sarcomas - solid cancers in the bone and muscle - the researchers found genetic changes that revealed different sub-types of the cancer, which, in turn, helped doctors choose the correct treatment. 4) Investigators also found more than 10% of ovarian cancers were probably inherited, offering insights into clinical care and potential testing of family members. 5) Homologous recombination deficiency was identified in 40% of high-grade serous ovarian cancer cases with 30% linked to pathogenic germline variants, highlighting the value of combined somatic and germline analysis. #medicine #research #healthcare #health #drugdevelopment #pharmaceutical #oncology #cancer #cancerresearch #biomarkers #innovation #technology